Foundayo results: how to read weight loss over time

Check who was studied before the percentage

The UK label describes the ATTAIN studies in adults with obesity or overweight, with and without type 2 diabetes. These are different groups of people. Keep their results apart and never merge them into one promise. Study reports also use different statistical methods for people who stopped treatment or missed measurements.

ATTAIN-1 followed adults without type 2 diabetes for 72 weeks. The trial used capsule doses, including 36 mg. The UK product is a film-coated tablet, and the label sets out how the two formulations compare. A headline percentage from these trials does not tell you what will happen on a starter tablet dose.

How to judge your own response

A daily tablet removes injections from your routine. Convenience alone does not guarantee you will keep taking the medicine or get a good result. The real test is whether you can stay on the prescribed treatment comfortably enough to gain a worthwhile benefit. Side effects which stop you eating or drinking enough are no success.

Note the time spent on each prescribed strength, any breaks and changes in activity or health. If you have diabetes, glucose results count too. Weight and HbA1c often improve at different speeds. Review both with your treating clinician.

Work out the change correctly

Percentage weight change uses your starting weight as the base. A fall from 100 kg to 90 kg is a 10% loss. The same 10 kg from a starting weight of 80 kg is 12.5%. This helps you read reports. Do not use it to set a fixed personal target.

Percentage points and relative percentages measure different things. Going from 12% to 15% is a three-percentage-point difference. Describing the higher figure as 25% greater sounds far bigger. Comparisons across separate trials add uncertainty, because the people and methods differ.

Follow the trend and the health gain

Each weigh-in shifts with hydration, bowel contents, menstrual cycle, clothing and time of day. Weigh in similar conditions and read the trend across several measurements. If weighing distresses you or prompts harmful behaviour, agree another way to monitor with your clinician.

Your goals may include mobility, symptoms, blood pressure, glucose control and eating and activity habits you can sustain. A plateau needs a calm review. A higher dose, a stricter diet or a second weight-loss medicine is not the automatic next step.

Published averages depend on who was able and willing to take part. Studies can exclude people with certain illnesses, past treatments or practical barriers. Treat trial results as a guide to possible benefit, and let your personal review cover what the trial missed.

Questions for your appointment

Ask whether the expected result comes from people with diabetes or without, and whether people who stopped treatment were counted. Discuss outcomes beyond weight, and how your prescriber will tell a weak response apart from too little time on treatment.